AI-generated summary
The authors pooled three small randomized trials of fractional CO2 laser for vulvar lichen sclerosus, involving 151 women followed for 18 to 32 weeks. They report no statistically significant improvement in symptom scores or disease severity compared with sham laser, topical clobetasol, or low-dose laser, and no adverse events were reported. The authors state that larger, adequately powered trials are needed.
- Participants
- 151
- Studies included
- 3
- Who or what was studied
- Adult women with confirmed vulvar lichen sclerosus
- Limits stated in the abstract
- The authors note only three small, short-duration trials were included, with substantial heterogeneity and no statistically significant benefit demonstrated.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Laser, Systematic review, Meta-analysis, Visual analogue scale, Sham, Heterogeneity, Risk of bias, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.